tapebrief
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

DXCM · Q2 2025 Earnings

Dexcom

Reported July 30, 2025

30-second summary

Dexcom delivered $1.157B in Q2 FY2025 revenue (+15% YoY) and raised the FY2025 revenue range to $4.600–$4.625B (14–15% growth), with non-GAAP gross margin landing at 60.1% versus a full-year target of ~62%. The print is clean — Type 2 non-insulin coverage expansion is now the explicit growth engine, supply dynamics have normalized, and the incoming-CEO tone (Jake Leach takes over January 1, 2026; Kevin Sayer remains CEO through year-end 2025) is unambiguously offensive. The unanswered question is the back-half margin ramp required to hit the 62% gross / 21% operating / 30% EBITDA full-year framework against a 60.1% / 19.2% / 28.3% Q2 FY2025 baseline.

Headline numbers

EPS

Q2 FY2025

$0.48

Revenue

Q2 FY2025

$1.16B

+15.0% YoY

Gross margin

Q2 FY2025

59.5%

Operating margin

Q2 FY2025

18.4%

Key financials

Q2 FY2025
MetricQ2 FY2025YoY
Revenue$1.16B+15.0%
EPS$0.48—
Gross margin59.5%—
Operating margin18.4%—

Guidance

Prior quarter data unavailable — comparison not possible.

Segment KPIs

Q2 FY2025
SegmentQ2 FY2025YoY
Sensor and Other Revenue$1.118B+18.0%
Hardware Revenue$0.039B-31.0%

Other KPIs

Q2 FY2025
SegmentQ2 FY2025YoY
U.S. Revenue$0.841B+15.0%
International Revenue$0.316B+16.0%
Non-GAAP Gross Margin60.1%—
Non-GAAP Operating Margin19.2%—
Adjusted EBITDA$327.6 million—
Adjusted EBITDA Margin28.3%—
Cash and Equivalents$2.93 billion—
FY2025 Revenue Guidance$4.600–$4.625 billion—

Management tone

Five distinct shifts emerge from the prepared remarks, all directionally bullish and all anchored in specific, falsifiable evidence rather than aspiration.

Supply has flipped from constraint to optionality. One quarter ago inventory was described as tighter than desired; this quarter management says "our supply dynamics are now in a much better position than they were even 90 days ago" and that Dexcom is "starting to rebuild our own stock of finished goods internally." The signal: the growth ceiling is no longer manufacturing, it's commercial pull-through — which sharpens accountability on the sales force.

Type 2 non-insulin has been promoted from opportunity to engine. The framing escalated to "reimbursement established for anyone with diabetes on the national formularies of the three largest commercial PBMs in the U.S." with an explicit 25M-person U.S. addressable population callout. This is the first quarter where management is treating Type 2 non-insulin as the dominant medium-term growth narrative rather than a secondary lever.

Stelo transitioned from experiment to channel. "The Stelo app has been downloaded more than 400,000 times" with prescribers now using it as a fallback for uncovered patients. That's a structural integration into the prescriber workflow, not a consumer side-project — and it monetizes the uncovered tail of the addressable population.

The competitive-bidding overhang has been reframed as a managed process. Management explicitly placed the earliest impact at 2027 and emphasized patient-continuity engagement with CMS. That removes a near-term overhang from the narrative without dismissing the risk to ~15% of Medicare fee-for-service revenue.

CEO-designate Jake Leach is setting an offensive tone. Kevin Sayer remains CEO through year-end 2025, with Leach assuming the role effective January 1, 2026. Leach's "I believe this company is just getting started" — combined with concrete evidence including a sales force "operating at a very high level" and "more than 100 health systems, either integrated or in the process of onboarding" to Epic EHR — signals the succession will not be a maintenance era. Investors should expect more aggressive capital deployment and product cadence.

Recurring themes management leaned on this quarter:

Type 2 non-insulin coverage expansion as primary growth leverSoftware-driven feature velocity and AI integration (food logging, EHR, wearable data)International market penetration via Dexcom 1 Plus and basal coverage deepeningSupply chain normalization enabling margin recovery and operational efficiencyNext-generation hardware roadmap (15-day G7, G8 with multi-analyte capability)Competitive positioning against pump-integrated CGM entrants

Risks management surfaced:

CMS competitive bidding proposal could compress pricing for ~15% of Medicare fee-for-service businessCompetitive CGM with insulin pump integration targeting type 1 installed baseType 2 non-insulin adoption below expectations in uncovered populationsSupply chain disruptions or manufacturing inefficiencies impacting customer continuityBroader market penetration slower than modeled for gestational diabetes and emerging indications

What to watch into next quarter

Gross margin trajectory — Q3 needs to print at or above ~62% non-GAAP for the FY ~62% framework to be credible without an outsized Q4. A repeat of 60% in Q3 is a yellow flag.

G7 15-Day System launch timing and pricing — management called it "highly-anticipated" but offered no firm launch window. Watch for a specific date and whether reimbursement parity is preserved at the 15-day SKU.

Type 2 non-insulin attach rate evidence — 25M TAM is the headline; the test is whether new-patient mix or script velocity shows up in Q3 sensor revenue acceleration above the +18% Q2 FY2025 pace.

CMS competitive bidding proposal milestones — any movement in the rulemaking calendar that pulls the 2027 timeline forward would re-introduce a discount on ~15% of Medicare FFS revenue.

Pump-integration competitive response — management's "2 million patient years on AAD systems" defense is the public posture; watch installed-base churn metrics or any change in U.S. new-patient share commentary as competitor pump-integrated CGMs scale.

Sources

  1. Dexcom Q2 2025 press release (Exhibit 99.1), filed with SEC: https://www.sec.gov/Archives/edgar/data/1093557/000109355725000241/dxcm06302025-exhibit991.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.